Sabrina Serani

Articles

Gintemetostat Shows Early Activity and Manageable Safety in Triple-Class Refractory Multiple Myeloma

December 7th 2025

Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

Lisaftoclax Displays Activity in R/R CLL/SLL

December 6th 2025

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma

December 6th 2025

Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.

Beyond the Genome: Exploring New Frontiers in NSCLC Management

November 15th 2025

Soo-Ryum (Stewart) Yang, MD, discusses biomarkers for ADCs, the actionability of tumor suppressor genes, and the advent of computational pathology.

Trastuzumab Rezetecan Displays PFS Benefit Vs Pyrotinib Plus Capecitabine in Pretreated HER2+ Breast Cancer

October 23rd 2025

Trastuzumab rezetecan reduced the risk of disease progression or death by 78% vs pyrotinib plus capecitabine in pretreatedHER2+ advanced breast cancer,

Atezolizumab Plus BCG Does Not Improve EFS Vs BCG Alone in BCG-Naive NMIBC

October 22nd 2025

Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.

Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer

October 20th 2025

Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.

Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma

October 19th 2025

Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.

Pembrolizumab/Lenvatinib Combo Is Active, Safe in Uveal Melanoma

October 19th 2025

Pembrolizumab plus lenvatinib was safe and active in HLA-A*02:01–negative and –positive uveal melanoma.

177-Lu-edotretide Prolongs PFS Compared With Everolimus in Grade 1/2 GEP-NETs

October 18th 2025

177-Lu-edotretide significantly improved survival outcomes vs everolimus for the treatment of patients with grade 1/2 GEP-NETs.

Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer

June 3rd 2025

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Rusfertide Shines as New Treatment Option in Polycythemia Vera

June 2nd 2025

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected Esophageal/GEJ Cancer

June 1st 2025

Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.

Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC

June 1st 2025

TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.

Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC

May 31st 2025

Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.

AI-Assisted Training Improves IHC Interpretation, Classification of HER2-Low and HER2-Ultralow Breast Cancer

May 22nd 2025

AI-assisted training of pathologists enhanced the accuracy of HER2 IHC scoring, potentially expanding eligibility for HER2-targeted treatments.

Adagrasib Yields Early Efficacy in STK11- and KRAS G12C–Mutant NSCLC

April 30th 2025

First-line adagrasib monotherapy demonstrated preliminary efficacy and tolerability in patients with SK11- and KRAS G12C–mutant NSCLC.

AU-007 Demonstrates Safety and Efficacy in Heavily Pretreated Solid Tumors

April 29th 2025

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with antitumor evidence.

Retrospective Analysis Explores Cabozantinib/Nivolumab vs Lenvatinib/Pembrolizumab in Frontline Advanced RCC

April 28th 2025

A retrospective analysis showed higher response rate for cabozantinib/nivolumab vs. lenvatinib/pembrolizumab in advanced RCC.

Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab Displays Efficacy in Advanced Urothelial Carcinoma

April 26th 2025

Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.